Figure 2.

WT1 peptide/MHC tetramer analysis of MLPC cells cultured with WT1 peptides and IL-2 for 14 days. MLPC was performed in a 200 μl medium-containing well by culturing 1-3x10⁵ MNCs of PB drawn from a CML patient at 4 weeks after the 20th administration of the WT1 peptide vaccination. MLPC cells in 20 wells (No. 1-20) were stained with FITC-CD8 and PE-modified-type WT1 peptide/MHC tetramer. Framed dot plots represent MLPC cells, which were evaluated as positive for WT1 peptide/MHC tetramer⁺CD8⁺ T cells. There were no MHC tetramer⁺CD8⁺ T cells in MLPC cells stained with HIV peptide/MHC tetramer.